Voclosporin licensed in China for transplantation
This article was originally published in Scrip
Executive Summary
Isotechnika Pharma saw its share price jump up by 30% earlier this week following news that it had signed a development and commercialisation deal with China's 3SBio for voclosporin, an investigational next generation calcineurin inhibitor for the prevention of organ rejection following transplantation and the treatment of autoimmune diseases.